NRG Oncology Board of Directors Appoints New At-Large Director

March 09 2021

PHILADELPHIA, PA – NRG Oncology, a National Cancer Institute (NCI) National Clinical Trials Network (NCTN) group focused on improving outcomes for adults with cancer through international clinical research, recently appointed Tashanna Myers, MD of the Department of Obstetrics and Gynecology at the University of Massachusetts Medical School, Baystate as an At-Large Director of the organization’s Board of Directors. This appointment was effective starting February 2021 for a 3-year renewable term.

myers-tashanna-1821103912.jpg

Dr. Myers has an expansive background in gynecologic oncology research and clinical trials as well as a history in academics and education. She is currently the Site Principal Investigator for the following trials: the NCI COVID-19 in Cancer Patients Study (NCCAPS); the NRG-GY022 study on carboplatin clearance predictors; a Phase III trial for intermediate risk, stage I/IIA cervical cancer patients that have been previously treated with an initial radical hysterectomy and pelvic lymphadenectomy, or surgery to remove the lymph node; the NRG-GY019 trial for primary low grade serous ovarian cancer; the NRG-GY006 trial for women with newly bulky stage IB2, stage II, IIB, or IVA uterine cervix cancer or stage II-IVA vaginal cancer, and several industry supported trials.

In addition to her clinical research experience, Dr. Myers has held leadership positions including her current roles as Medical Director and Division Chief of the Department of Obstetrics and Gynecology at the University of Massachusetts Medical School, Baystate and previous positions as Chair of the Diversity Committee at Baystate Medical Center. She has received several teaching honors from the Baystate OB/GYN Residency Program and Tufts University School of Medicine, and has been invited to speak at national presentations such as the Society for Gynecologic Oncology Annual Meeting.

“I look forward to utilizing my experiences and expertise to help this organization continue to contribute clinical meaningful research results and expand upon ways we can improve our current strategies and methods for the future,” stated Dr. Myers.

“In her new role, Dr. Myers will be a tremendous asset to the leadership of the NRG Oncology Board of Directors and helping NRG Oncology achieve their research goals and adhere to their mission,” added Robert S. Mannel, MD, an NRG Oncology Group Chair and the Director of the Stephenson Cancer Center at the University of Oklahoma Health Sciences Center.

About NRG Oncology

NRG Oncology conducts practice-changing, multi-institutional clinical and translational research to improve the lives of patients with cancer. Founded in 2012, NRG Oncology is a Pennsylvania-based nonprofit corporation that integrates the research of the legacy National Surgical Adjuvant Breast and Bowel Project (NSABP), Radiation Therapy Oncology Group (RTOG), and Gynecologic Oncology Group (GOG) programs. The research network seeks to carry out clinical trials with emphases on gender-specific malignancies, including gynecologic, breast, and prostate cancers, and on localized or locally advanced cancers of all types. NRG Oncology’s extensive research organization comprises multidisciplinary investigators, including medical oncologists, radiation oncologists, surgeons, physicists, pathologists, and statisticians, and encompasses more than 1,300 research sites located world-wide with predominance in the United States and Canada. NRG Oncology is supported primarily through grants from the National Cancer Institute (NCI) and is one of five research groups in the NCI’s National Clinical Trials Network.

www.nrgoncology.org

Stay current with science. Sign up for our newsletter.

Support NRG Oncology.
Help Our Cause.

We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More

Donate Today

NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.